Prothena to Report Second Quarter 2026 Financial Results on August 6 July 30, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the close of the U.S. financial markets. Consistent with past practice, [...]
ARIS Recognized as a Leader in First Gartner® Magic Quadrant™ for Digital Twin of an Organization Platforms, Believes This Reinforces Need for Trusted Governance and Control of Enterprise AI July 30, 2026 ARIS, the process context platform enabling enterprise AI deployment, today announced its recognition as a Leader in the inaugural Gartner Magic Quadrant for Digital Twin of An Organization (DTO) Platforms – where it believes agentic AI, autonomous workflows, and enterprise governance converge. As enterprises move from AI experimentation to autonomous agent deployment, a critical challenge [...]
Kingswood Capital Management Raises $4 Billion Across Two Oversubscribed Middle-Market Funds July 30, 2026 The firm’s fourth institutional fundraise more than doubles its assets under management, reaching over $7 billion
Cognitive Credit Launches Emerging Markets Corporate Bond Coverage July 30, 2026 Cognitive Credit, the leading provider of corporate credit data and analytics technology, today announces the launch of its Emerging Markets (EM) Corporate Bond dataset, expanding its global coverage to over 3,500 global issuers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260730435988/en/ This new coverage universe includes detailed historical financial data and full [...]
Scottish Government Selects Planet for AI-Enabled Monitoring to Support Sustainable Agricultural Reform July 30, 2026 Planet Labs Germany, a leading provider of daily data and insights about change on Earth, recently announced that it was selected for a 7-figure award from the Scottish Government’s Agricultural and Rural Economy Directorate. Under this one-year agreement, Planet will deliver PlanetScope data and advanced analytics to support Scotland’s Agricultural Reform Route Map. Secured through [...]
Mary Kay Releases 2026 Sustainability Report Highlighting Transformative Progress Across Social, Economic, and Environmental Impact Globally July 30, 2026 Beauty Leader Ranked #8 on Forbes’ 2026 Best Brands For Social Impact List
Reply S.p.A: The Board of Directors Approves the Half-year Financial Report as of 30 June 2026 July 30, 2026 All economic and financial indicators grew: Consolidated turnover of €1,311.9 million (1,221.3 in H1 2025); EBITDA of €233.2 million (223.7 in H1 2025); EBIT a of €189.7 million (188.4 in H1 2025); Pre-tax profit of €194.1 million (179.4 in H1 2025).
De’ Longhi Group: a Quarter of Robust Revenue Growth of 8.4% and Solid Margin Expansion Drives an Upward Guidance Revision July 30, 2026 Substantial expansion in Professional and acceleration in Household drive growth and margins, enabling further investments in marketing and product innovation as part of the Group's continuous strategic evolution
DNA Payments Launches DNA Engage, a New Way for Businesses to Connect With Customers July 30, 2026 DNA Payments has launched DNA Engage, an innovative platform powered by Taployo that helps merchants turn every payment into an opportunity to build customer relationships, drive loyalty, and gain actionable business insights. DNA Engage enables businesses of any size to turn their receipts into branded post-purchase experiences through personalised receipts, targeted promotions, Google Reviews, surveys, [...]
Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential July 30, 2026 VRB-103, a potential once-weekly, selective oral amylin analog, is being evaluated in a Phase 1 study as both a monotherapy and in combination with VRB-101 (oral ecnoglutide), a once-weekly oral GLP-1 analog Once-weekly oral dosing of both VRB-103 and VRB-101 enabled by clinically validated, potential best-in-class peptide delivery platform VRB-103 is the first known, once-weekly oral amylin analog currently in clinical development Initial data currently anticipated by the end of 2026
